



Corporate Action Notice

BNY MELLON
DEPOSITORY RECEIPTS

December 13, 2011

Ratio Change and Reverse Split

Name: Novogen Limited

DR CUSIP: 67010F103

Ratio: 1 : 5 (ADR:ORD)

Symbol: NVGN

Please be advised Novogen Limited (the “Company”) has instructed BNY Mellon, as Depositary, to effect a ratio change on the American Depository Receipt (“ADR”) program. The ADR Share ratio will change from one (1) American Depository Share (“ADS”) representing five (5) deposited shares to one (1) ADS representing twenty five (25) deposited shares.

As a result, the Novogen Limited ADR program will undergo a reverse split of one (1) new ADS for every five (5) old ADSs held.

Exchange Rate- 1 new Novogen Limited ADS for every 5 old ADSs

New CUSIP- 67010F 202

New Ratio:- 1 ADS: 25 Shares

Effective Date- January 3, 2012

Registered ADR holders will receive a letter of transmittal in order to surrender their old ADSs on a mandatory basis and receive the new ADSs. DTC participants’ ADSs will be automatically surrendered and exchanged for new ADSs. The Depositary will overstamp the existing ADR certificates to reflect the new parameters.

Fractional ADSs will not be issued. The Depositary will aggregate all fractional shares, and will attempt to sell those shares in order to distribute cash-in-lieu of fractions.

To learn more about Depositary Receipts and issuer programs, please contact our marketing desks:

New York

Ravi Davis

Vice President

+1 212 815-4245

ravi.davis@bnymellon.com

London

Damon Rowan

Vice President

+44 207 964 6527

damon.rowan@bnymellon.com

Hong Kong

Joe Oakenfold

Vice President

+852 2 840 9717

joe.oakenfold@bnymellon.com

BNY Mellon collects fees from DR holders pursuant to the terms and conditions of the DRs and the deposit agreement under which they are issued. From time to time, BNY Mellon may make payments to the issuer to reimburse and / or share revenue from the fees collected from DR holders, or waive fees and expenses to the issuer for services provided, generally relating to costs and expenses arising out of establishment and maintenance of the DR program. BNY Mellon may also transact with affiliated brokers and dealers.

This information and data is provided for general purposes only; it is not investment advice and should not be used for any investment decisions nor trading purposes. BNY Mellon does not warrant or guarantee the accuracy, timeliness or completeness of this announcement and shall have no liability for investment or other decisions based hereon, including market values loss on the sales or purchase of securities or other instruments or obligations. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.